Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Harvard Business School
AstraZeneca
McKesson
Medtronic

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,025,899

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,025,899 protect, and when does it expire?

Patent 8,025,899 protects KALETRA and is included in one NDA.

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty patent family members in thirty-six countries.

Summary for Patent: 8,025,899
Title:Solid pharmaceutical dosage form
Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50.degree. C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
Inventor(s): Berndl; Gunther (Herxheim, DE), Rosenberg; Joerg (Ellerstadt, DE), Liepold; Bernd (Dossenheim, DE), Breitenbach; Joerg (Mannheim, DE), Reinhold; Ulrich (Heidelberg, DE), Alani; Laman (Foster City, CA), Ghosh; Soumojeet (Lansdale, PA)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/925,442
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,025,899
Patent Claim Types:
see list of patent claims
Dosage form; Formulation;

Drugs Protected by US Patent 8,025,899

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-002 Nov 9, 2007 RX Yes No   Request a Trial   Request a Trial Y   Request a Trial
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-001 Oct 28, 2005 RX Yes Yes   Request a Trial   Request a Trial Y   Request a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,025,899

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 055734   Request a Trial
Argentina 077411   Request a Trial
Australia 2006216856   Request a Trial
Brazil 122012031169   Request a Trial
Brazil PI0609173   Request a Trial
Canada 2598827   Request a Trial
Canada 2821046   Request a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Mallinckrodt
McKesson
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.